Pyrazinamide Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg, 500 mg, 750 mg ,1000 mg
Reference Brands: Tebrazid
Category:
Antibiotics
Pyrazinamide Tablet is a medicine that is used for the treatment of Tuberculosis and other conditions.
Pyrazinamide Tablet contains Pyrazinamide as an active ingredient.
Pyrazinamide Tablet works by preventing growth of bacteria that causes tuberculosis.
Pyrazinamide Tablet is available in Tablets
and strengths such as 250 mg, 500 mg, 750 mg ,1000 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pyrazinamide Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pyrazinamide Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pyrazinamide is an antibiotic medication primarily used for the treatment of tuberculosis. It is most effective when used in combination with other antituberculosis drugs such as rifampicin, isoniazid, and either streptomycin or ethambutol. Pyrazinamide is specifically indicated for active tuberculosis and is not generally recommended for latent tuberculosis infections. Its use is always as part of a combination therapy, often administered under directly observed therapy (DOT) to ensure adherence and treatment effectiveness.
Pyrazinamide is never used alone and has no other approved medical uses. It is designed to target Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and is ineffective against other mycobacterial species, including Mycobacterium bovis and Mycobacterium leprae, which are naturally resistant to the drug. By working synergistically with other first-line antitubercular agents, pyrazinamide helps shorten the duration of treatment and prevent the development of drug-resistant tuberculosis strains. Its role in combination therapy is essential for achieving successful treatment outcomes and controlling the spread of tuberculosis globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing